Monday, April 27, 2015

Tuesday Features

In conversation with Dr. Shai Yarkoni

In conversation with Dr. Shai Yarkoni

Dr. Shai Yarkoni As a co-founder and CEO of Cellect Biotechnology (TASE:CLBD), Dr. Shai Yarkoni has more than 15 years of clinical and management experience in the biopharmaceutical industry. He is the founder of five start-ups in the life-sciences field, and serves on the board of noted institutes in Israel and the world. Prior to founding Cellect,... [Read more of this feature]


In conversation with Greg Trudel

In conversation with Greg Trudel

Greg Trudel As president and CEO of Encision (OTCQB:ECIA), Greg Trudel, who moved into the executive suite in December 2013, has always had a strong interest in energy, dating back to various leadership posts with ConMed Electrosurgery, SilverGlide Surgical Technologies, and Stryker. Most recently, he was global director of marketing for a division... [Read more of this feature]


Relmada championing four pain drug candidates

Relmada championing four pain drug candidates

Startup Relmada Therapeutics (OTCQB:RLMD) is in the enviable position of having multiple shots on goal in the world’s largest drug prescription market: the treatment of pain. Dr. Eliseo Salinas “It is very unusual for a startup or even a mid-sized biotech company to have four different medications in clinical development for pain relief,” Dr.... [Read more of this feature]


More Posts From Tuesday Features

Briefs

HCW starts Stemline Therapeutics at buy

HCW starts Stemline Therapeutics at buy

H.C. Wainwright has initiated coverage of Stemline Therapeutics (NASDAQ:STML) with a “buy” rating and a 12-month price target of $38. The stock closed at $16.58 on Friday. Stemline is focused on the development of novel anti-cancer therapeutics that eradicate both the tumor bulk and cancer stem cells (CSCs). “Stemline represents a unique investment... [Read more of this brief]


HCW starts DARA BioSciences at buy

HCW starts DARA BioSciences at buy

H.C. Wainwright has launched coverage of DARA BioSciences (NASDAQ:DARA) with a “buy” rating and a target price of $2. The stock closed at 77 cents on Thursday. DARA’s core franchise is comprised of niche-marketed therapeutics encompassing cancer supportive care. The company’s sole developmental compound, KRN5500, is a spicamycin analog that... [Read more of this brief]


Nuvo outlines new WF10 Phase 2 trial

Nuvo outlines new WF10 Phase 2 trial

Nuvo Research (TSX:NRI) has provided additional details of the 2015 WF10 Phase 2 trial to assess WF10 for the treatment of allergic rhinitis. The 2015 WF10 trial will be a randomized, double-blind, placebo-controlled, single-center trial to assess the efficacy, safety and tolerability of a regimen of five WF10 infusions. The trial will enroll about... [Read more of this brief]


Maxim starts Cardio3 BioSciences at buy

Maxim starts Cardio3 BioSciences at buy

Maxim Group has initiated coverage of Cardio3 BioSciences (BRU:CARD) with a “buy’ rating and price target of €61. The stock closed at €52.51 on Tuesday. “With pivotal programs in autologous cardiopoietic stem cell heart therapy underway in Europe and one about to begin in the U.S., combined with early stage CAR-T programs (Phase 1 is underway),... [Read more of this brief]


biOasis gets European patent for Transcend

biOasis gets European patent for Transcend

The European patent for the use of Transcend to deliver enzymes to treat lysosomal storage disease to the brain has now been fully issued to biOasis Technologies (OTCQX:BIOAF; TSX.V:BTI) and has cleared the notice of opposition period. This completes the company’s goal to obtain patent protection for jurisdictions around the globe where patent... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+